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Summary
Venous thromboembolism (VTE) is a significant cause of morbidity 
and mortality in Europe. Data from real-world registries are necessary, 
as clinical trials do not represent the full spectrum of VTE patients 
seen in clinical practice. We aimed to document the epidemiology, 
management and outcomes of VTE using data from a large, observa-
tional database. PREFER in VTE was an international, non-interven-
tional disease registry conducted between January 2013 and July 
2015 in primary and secondary care across seven European countries. 
Consecutive patients with acute VTE were documented and followed 
up over 12 months. PREFER in VTE included 3,455 patients with a 
mean age of 60.8 ± 17.0 years. Overall, 53.0 % were male. The major-
ity of patients were assessed in the hospital setting as inpatients or 
outpatients (78.5 %). The diagnosis was deep-vein thrombosis (DVT) 
in 59.5 % and pulmonary embolism (PE) in 40.5 %. The most common 
comorbidities were the various types of cardiovascular disease (ex-
cluding hypertension; 45.5 %), hypertension (42.3 %) and dyslipidae-
mia (21.1 %). Following the index VTE, a large proportion of patients 
received initial therapy with heparin (73.2 %), almost half received a 
vitamin K antagonist (48.7 %) and nearly a quarter received a DOAC 
(24.5 %). Almost a quarter of all presentations were for recurrent VTE, 
with >80 % of previous episodes having occurred more than 12 
months prior to baseline. In conclusion, PREFER in VTE has provided 
contemporary insights into VTE patients and their real-world manage-
ment, including their baseline characteristics, risk factors, disease his-
tory, symptoms and signs, initial therapy and outcomes.
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Introduction
Deep-vein thrombosis (DVT) and pulmonary embolism (PE; col-
lectively termed venous thromboembolism [VTE]) are major 
healthcare burdens in Europe. Indeed, VTE is highly prevalent in 
Europe and is the third most frequent cardiovascular (CV) disease 
(1, 2).
Though data from a number of prior VTE registries have been 
reported (3, 4), a great deal of the available information on the 
clinical management of VTE is drawn from patients included in 
clinical trials. Due to complex inclusion and exclusion criteria, 
these patients are often not representative of the full spectrum of 
VTE patients. Furthermore, the management of patients with VTE 
has changed substantially following the introduction of new forms 
of patient care, such as home treatment, office-based care, and the 
development of new direct oral anticoagulants (DOACs). The ma-
jority of the modifications to management strategies are related to 
the intrinsic features of the available agents (i. e. larger therapeutic 
windows removing the necessity for close laboratory monitoring) 
while others (such as reduced hospital stay) are related to socio-
economic and health economic factors. Considering that neither 
the degree of implementation nor impact of these amendments 
appear to have been quantified in a real-world setting, acquisition 
of contemporary epidemiology data on the management of VTE 
in Europe is warranted.
Based on this background, we developed an international, non-
interventional, prospective disease registry enrolling consecutive 
VTE patients in both primary and secondary care across different 
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countries in Europe (5). The aim was to document the epidemiol-
ogy, management and outcomes of VTE in a large population that 
was not limited by stringent clinical trial inclusion/exclusion crite-
ria.
Materials and methods
PREFER in VTE was a prospective, non-interventional, disease 
registry including patients from seven European countries (Aus-
tria, France, Germany, Italy, Spain, Switzerland and the UK). For 
the present analysis, Germany (D), Austria (A), and Switzerland 
(CH) were combined into one region, henceforth referred to as 
“DACH”. Prior to study commencement, the registry protocol was 
approved by the responsible ethics committees for the participat-
ing countries and the relevant hospital-based institutional review 
boards. All patients enrolled in the registry first provided written 
informed consent. The design and methods of the PREFER in VTE 
registry have previously been described (5), though a brief over-
view of the design, patient inclusion criteria and data collection 
methods is provided below.
Patients
Patients eligible for participation in the registry were aged at least 
18 years, had symptomatic, objectively confirmed acute VTE 
(either first-time or recurrent) diagnosed in the last two weeks and 
were not simultaneously participating in a double blind interven-
tional study. Patients were enrolled between January 2013 and 
2014, and those in the present study were followed up through to 
July 2015.
Data collection
Baseline data were collected in hospitals (on an in- or outpatient 
basis) or specialised centres at the time of acute VTE diagnosis. 
The physician was responsible for the input of data pertaining to 
the period prior to baseline, which was based on a medical history 
and examination of the patient’s medical records. Follow-up data 
were collected at 1 month (either during a visit or telephone inter-
view) and at 3, 6 and 12 months via a telephone interview with a 
medically-trained professional. Specially designed patient diaries 
were kept by each participant to aid their responses to the inter-
view questions and limit recall bias. Furthermore, clear guidelines 
were adhered to by interviewers in order to standardise the data 
collection process across the population.
Definitions
Acute VTE was defined as either distal or proximal DVT, PE or 
both. Cancer was defined as being active if patients were receiving 
ongoing treatment, whereas a history of cancer was applicable to 
all patients with a cancer diagnosis. Cardiovascular disease was de-
fined as one of the following: documented coronary artery disease 
or vascular disease (e. g. peripheral artery disease or aortic plaque), 
transient ischaemic attack (TIA); stroke; congestive heart failure or 
left ventricular systolic dysfunction. Hypertension was defined as a 
blood pressure >130/80 mmHg in patients with diabetes, and a 
SBP >140 mmHg or diastolic blood pressure (DBP) >90 mmHg in 
those without diabetes. Liver disease was considered present in pa-
tients with chronic hepatic disease or biochemical evidence of sig-
nificant hepatic derangement. Renal insufficiency was classed into 
mild (reduction of the glomerular filtration rate [GFR] to 60–89 
ml/min with kidney damage), moderate (reduction in GFR to 
30–59 ml/min), severe (reduction in GFR to 15–29 ml/min) or 
end-stage renal disease.
Bleeding risk was assessed using the HAS-BLED score. In this 
score, one point is awarded for each of the following, up to a maxi-
mum of 9 points: hypertension (systolic blood pressure [SBP] >160 
mmHg); abnormal renal function (transplantation, chronic dialy-
sis, or serum creatinine ≥200 µmol/L); abnormal liver function 
(chronic hepatic disease or biochemical evidence of significant he-
patic derangement); stroke (history of stroke); bleeding history or 
predisposition (anaemia); labile INR (time in therapeutic range 
<60 %); advanced age (>65 years); concomitant drugs/alcohol (one 
point for use of antiplatelet agents and/or non-steroidal anti-in-
flammatory drugs, plus one point for excessive alcohol consump-
tion) (6). To assess bleeding outcomes, the International Society of 
Thrombosis and Haemostasis (ISTH) definitions of major, clini-
cally relevant non-major (CRNM) and nuisance bleeding were 
used (7).
Statistics
All binary and categorical outcomes were expressed as frequencies 
(percentages). Means and standard deviations (SD) were given for 
normally distributed numerical variables and medians were used 
for non-parametric data. For all data presented here, values are 
based on the number of patients for whom the particular data 
point was available and fully completed, with corresponding de-
nominators. Missing/unknown values are excluded for each factor. 
Statistical comparisons were carried out using Chi-square and 
t-tests, with a p-value <0.05 considered significant.
Results
In the PREFER in VTE registry, 3,464 patients were initially regis-
tered. Of these, 3,455 (99.7 %) had evaluable baseline data and 
were included in the current analysis (Figure 1). In the overall 
population, the majority were assessed at a hospital (78.6 %) as in-
patients or outpatients, with only a small proportion undergoing 
office-based assessment (21.4 %). The hospital assessment rate was 
higher for PE than for DVT patients (92.5 % vs 69.1 %; p<0.0001).
Patient characteristics
For all patients included in the analysis, the total mean age was 
60.8 years, 53.0 % were male, the mean body mass index (BMI) 
was 27.9 kg/m2, 31.5 % had a history of smoking, and 17.3 % a his-
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tory of alcohol use (Table 1). No substantial differences between 
DVT only and PE ± DVT groups were seen with respect to these 
demographics. Common comorbidities were CV disease (45.5 %), 
followed by hypertension (42.3 %), and dyslipidaemia (21.1 %). 
Each of these comorbidities were more prevalent in patients with 
PE ± DVT than in those with DVT alone. Before baseline examin-
ation, coronary artery disease was present in 3.8 % of all patients, 
myocardial infarction (MI) and atrial fibrillation (AF) had oc-
curred in 3.3 % and 3.5 %, respectively, 2.3 % had suffered a tran-
sient ischaemic attack (TIA) and 2.4 % had experienced a stroke. 
Both AF and arterial embolization were more common in the PE 
patients.
VTE-related history and bleeding risk
A history of varicose veins (20.2 %) and cancer (16.0 %) were 
prevalent in the study population, with similar proportions seen in 
the DVT only and PE ± DV groups (Table 2). Overall, 23.5 % of 
patients had a history of VTE, applying to a significantly higher 
proportion of the DVT only compared to the PE ± DVT group 
(25.7 % vs 20.2 %; p=0.0002) (Table 2). More DVT than PE ± DVT 
patients had experienced a previous DVT episode (24.5 % vs 
15.3 %; p<0.0001), while more PE ± DVT than DVT patients had 
experienced a previous PE episode (10.0 % vs 5.2 %; p<0.0001).
The majority of previous DVTs had occurred >12 months be-
fore baseline (82.7 %) and had resulted in hospitalisation in 42.2 % 
of cases. Similarly, the majority of previous PE episodes (84.5 %) 
had also occurred >12 months before baseline, though a substan-
tially higher proportion of patients had been hospitalised as a re-
sult (84.2 %). Of the patients with a previous DVT episode, 12.3 % 
were receiving ongoing VTE treatment at baseline. Of patients 
with a previous PE episode, 13.1 % were receiving ongoing VTE 
treatment at baseline. This corresponded to only a small propor-
tion of the overall population.
A total of 133 out of 3,451 patients had a history of bleeding 
events before the baseline visit (Table 3). Of those bleeding events, 
CRNM bleeding was the most common (51.1 %). Seventeen pa-
tients (12.8 %) had a history of intracerebral bleeding. Based on the 
HAS-BLED score, bleeding risk was low in the majority of patients 
(56.7 % had a 0 or 1 points assigned) with no major difference be-
tween patients experiencing DVT only (59.4 %) and PE ± DVT 
(52.7 %) (Figure 2). Patients with 2 or more points on the HAS-
BLED score made up >40 % of the cohort. Fourteen percent had a 
HAS-BLED score of 3 or more points (12.9 % DVT, 15.5 % PE ± 
DVT), indicating high risk. The frequencies of individual elements 
of the HAS-BLED score were also fairly similar between groups.
VTE diagnosis (overall and by type of VTE)
Upon diagnosis, the most frequent symptoms and signs in relation 
to DVT were pain (82.8 %) and the swelling of extremities (73.3 %) 
(Table 4). The most frequent symptoms of PE were dyspnea 
(75.6 %) and chest pain (45.5 %). Only 2.2 % of DVT patients and 
6.9 % of PE patients were asymptomatic at the time of diagnosis. 
The median time between onset of symptoms and first medical 
contact was 19 hours (h). This was longer for the DVT population 
(48 h) compared to patients suffering from PE (7 h).
In the DVT population, the majority of patients were diag-
nosed using ultrasound (98.6 %), with a median of 4 days between 
symptom onset and ultrasound diagnosis. CT/MRI was used for 
1.9 % of diagnoses, and venography for 1.6 %.
In the PE population the majority of patients were diagnosed 
using CT/MRI (81.7 %) with a median delay of 2 days between 
onset of symptoms and CT/MRI diagnosis. A further 17.5 % were 
diagnosed using echocardiography, and less than 10 % were diag-
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Figure 1: Patient flow. DVT, deep-vein throm-
bosis; PE, pulmonary embolism.
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nosed using perfusion scan, pulmonary angiography, venous study 
or ventilation scan.
VTE treatment strategy
At baseline, the majority of patients in the overall population 
(73.2 %) were documented as receiving heparin, with a significant 
number receiving vitamin K antagonists (VKAs, 49.3 %) and 
DOACs (24.9 %). In general, a greater proportion of PE ± DVT pa-
tients appeared to be taking heparin and VKAs than patients with 
DVT alone (84.9 % and 58.0 %, vs 65.2 % and 43.3 %, respectively), 
while the opposite was true for DOACs (21.5 % vs 27.2 %, respect-
ively) (Figure 3A). For the subset of countries in which DOACs 
were launched at study initiation, the aforementioned trend was 
also evident (Figure 3B). However, the proportion of patients tak-
ing DOACs was generally higher than the overall population for 
both study groups (42.1 % of DVT patients and 35.9 % of PE ± 
DVT patients) and fewer patients were receiving heparin in the 
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DVT group (56.6 %). DOACs were more frequently used in 
younger patients, those without renal impairment, those at low 
risk of bleeding, and those with fewer comorbidities (such as dia-
betes).
At 1-month follow-up, the most prevalent treatment in the 
overall population was VKA (53.4 %) followed by DOACs (25.4 %) 
and heparin (18.9 %). In general, a greater proportion of patients 
with DVT only were taking heparin (20.2 % vs 16.9 %) or DOACs 
(27.6 % vs 22.2 %) compared to PE ± DVT patients (Figure 3C). 
Conversely, use of VKAs was more prevalent in the PE ± DVT 
group (61.8 % vs 47.7 %). Again, the same trends were true for 
countries in which DOACs were launched at study initiation (Fig-
ure 3D). However, the proportion of patients treated with DOACs 
at 1 month was generally higher (42.6 % and 35.9 % for DVT and 
PE ± DVT groups, respectively) with lower levels of heparin use 
(11.6 % and 9.6 % for DVT and PE ± DVT groups, respectively) 
than in the corresponding overall groups.
Outcomes 12 months after diagnosis
Twelve months after diagnosis, 230 patients had died (6.7 % of all 
those 3,455 patients evaluable at baseline), with similar rates in 
each group. The PE recurrence rate was generally low (1.3 % over-
all), the DVT recurrence was higher (3.9 %), largely owing to a 
higher proportion of DVT only patients experiencing a further 
DVT event (5.6 % vs 1.7 % for PE ± DVT patients; p<0.0001). 
Major bleeding occurred in 1.5 %, clinically-relevant non-major 
bleeding (CRNM) in 3.1 %, and 4.2 % of patients experienced nui-
sance bleeding. The only difference between groups was found for 
CRNM bleeding, with significantly more events occurring in the 
PE ± DVT group (4.2 % vs 2.3 %; p=0.008). In those having a fol-
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Table 2: VTE-related 
risk factors.
Previous first episode of VTE
Previous episode of DVT




 Active cancer / ongoing treatment
Major surgery or trauma within past 
three months
Bone fractures/soft tissue trauma
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low-up at 12 months available, rates of the individual components 
of the non-fatal ischaemic events (MI, stroke, TIA and arterial em-
bolism) were extremely low (≤0.5 %) and similar between groups, 
with the exception of arterial embolisation, which was more preva-
lent in DVT only patients (0.5 % vs 0.1 % for PE ± DVT patients; 
p=0.045) (Table 5). Hospital admission occurred in 17.5 % of pa-
tients overall, though greater numbers of PE ± DVT patients were 
hospitalised (21.5 %) compared to DVT only patients (14.5 %; 
p<0.0001).
Discussion
PREFER in VTE was a multinational registry which enrolled over 
3,400 patients from seven European countries (5). This multi-
centre observational database aimed to document VTE clinical 
management practices and patient outcomes in a wide-ranging 
sample of sites. These encompassed the spectrum of care from 
small to specialist primary care practices, small to very large sec-
ondary care institutions, and both academic and non-academic 
sites. PREFER in VTE therefore provides a snapshot of the VTE 
landscape in Western European countries, including the real-
world use of new DOACs.
Patient characteristics
Patients in the PREFER in VTE registry were generally older (aver-
age 61 years) compared to those in recent phase 3 clinical trials 
(ranging from 55 to 58 years) (8). Conversely, our patients were 
similar in age or younger than those in inception cohorts (ranging 
from 62–65 years) (9, 10). About half (53 %) of the PREFER in 
VTE patients were males compared with 53.0–61 % in clinical 
trials (8). However, most VTE inception cohorts show higher per-
centages of females (9, 10). This is likely to be partly due to recur-
rences being more common in males; hence registries and clinical 
trials contain a higher proportion of male subjects, despite first 
episodes being more common in females. The mean BMI was 27.9 
kg/m2, similar to what has been described in both clinical trials 
and inception cohorts (8, 10, 11). The frequency of risk factors for 
VTE (such as cancer and a past history of VTE) were similar to 
clinical trials. Over 23 % of all presentations were for recurrent 
VTE disease, with the majority of previous episodes (>80 %) hav-
ing occurred more than 12 months previously. This is consistent 
with the view that VTE should be considered as a chronic disease 
(12). Around 4 % of patients had experienced bleeding prior to de-
veloping the index VTE. Given that such patients have not been 
included in clinical trials, their clinical course is of interest.
Our study may supplement the information already obtained 
from databases such as the Registro Informatizado de Enfermedad 
ThromboEmbólica (RIETE) registry, an ongoing, international, 
prospective registry of acute VTE patients which was started in 
2001 (3). In a 2010 analysis including 22,133 patients, the propor-
tion of patients diagnosed with PE was slightly higher compared to 
the present study (PE: 47 % vs 41 %), as was the mean age (65 vs 60 
years) (13). This may be for a number of reasons related to differ-
ences in study design. Although RIETE also excluded individuals 
participating in clinical trials, analyses tend to pool data from pa-
tients who were diagnosed over a wide range of years (i. e. between 
2001 and 2008) (13). Conversely, the present analysis is based on 
those diagnosed between 2013–2014. This means that patient 
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Figure 2: Bleeding risk by type of VTE according to overall HAS-BLED 
score and individual components (n=3,292). DVT, deep-vein thrombo-
sis; PE, pulmonary embolism. In the HAS-BLED score, one point is assigned 
for each of the criteria in the lower panel (9 points max). *Systolic blood 
pressure >160 mmHg. **Antiplatelet agents or non-steroidal anti-inflamma-
tory drugs. ‡Dialysis, transplant, Cr >2.26 mg/dl or >200 µmol/l. ‡‡Cirrhosis 
or bilirubin >2× normal or AST/ALT/AP >3× normal. §time in therapeutic 
range <60 %.
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Table 4: Symptoms and signs at baseline.
DVT (n=2,056)
 Pain
 Swelling of extremity
 Calf tenderness
 Discoloration







































numbers are significantly larger in RIETE analyses, though the 
registry is less geared towards identifying recent shifts in the clini-
cal landscape which may lead to different results. Secondly, the 
majority of RIETE patients were diagnosed at hospitals in Spain, as 
well as some in France, Italy, Israel and Brazil. This suggests that 
sociodemographic biases are likely to be different compared to the 
present study. Furthermore, hospital diagnosis in the RIETE analy-
sis occurred either following symptomatic emergency room pres-
entation or during hospitalisation for another cause, with both set-
tings indicating more severe disease, high comorbidity levels, and 
more specialised care. Conversely, the mixture of sites in the 
PREFER in VTE registry allows for the inclusion of patients diag-
nosed in a range of settings, and therefore a greater diversity of 
VTE presentation. Interestingly, despite the aforementioned differ-
ences, the reported rates of bleeding events prior to baseline were 
fairly comparable in RIETE and PREFER in VTE studies (3.0 % vs 
3.9 %, respectively), suggesting that this may be a consistent factor 
in VTE patients. Unlike RIETE, our study routinely collected data 
on factors such as resource utilisation, Quality of Life, and the con-
venience/burden of anticoagulation treatment, with both general 
and VTE-specific assessments carried out. Both registries provide 
valuable and interesting data which may be used to broaden our 
understanding of the VTE clinical landscape. It will be interesting 
to compare the results of PREFER in VTE with upcoming Euro-
pean registries, such as the Global Anticoagulant Registry in the 
Field for Venous Thromboembolism (GARFIELD-VTE) (14).
Symptoms and signs of VTE
The presentation of symptoms and signs and the methods used for 
diagnosis in the present study were consistent with previous data 
(15, 16). Asymptomatic PE and DVT made up 6.9 % and 2.2 % of 
the cohort, respectively. A large difference in the time between 
clinical onset of symptoms and the time of diagnostic testing was 
seen between DVT and PE patients, with a shorter duration in the 
latter population. This is expected, given that PE is the more seri-
ous form of VTE presentation. Patients not usually enrolled in 
clinical trials were included in the registry, including those with a 
history of bleeding (3.9 %), women who are pregnant (1.1 %) or in 
puerperium (1.0 %), and intravenous drug users (0.3 %).
Comorbidity and bleeding risk
In the present study, we used the HAS-BLED score as the principal 
measure of bleeding risk. Scores were not seen to vary greatly be-
tween DVT and PE patients, with over 40 % of the total population 
having a value consistent with moderate-to-high risk. Comorbid-
ities were not infrequent; renal impairment and liver disease are 
important factors to be considered in bleeding risk assessment and 
occurred in 6.2 % and 2.6 % of patients, respectively. The clinical 
course of these patients will be of substantial interest, as patients 
with higher bleeding risk profiles are not typically included in 
clinical trials.
Although the HAS-BLED score itself was not originally intend-
ed for use in assessing VTE patients, having been developed for 
AF patients (6), each of its individual components is a validated 
risk factor for bleeding in VTE outlined by the 2016 CHEST 
Guideline and Expert Panel Report on Antithrombotic Therapy 
for VTE Disease (17). This is with the exception of hypertension, 
which was recently identified as a predictor for bleeding in 8,240 
VTE patients treated with a factor Xa inhibitor or warfarin (18). 
Indeed, 2016 ESC Guidelines for the Management of AF state that 
all of the HAS-BLED components should be used for the identifi-
cation of modifiable risk factors in anticoagulated patients (19). 
Furthermore, several groups have presented evidence for the use of 
the HAS-BLED score in VTE populations (20, 21), with one 
reporting HAS-BLED to show the highest predictive value com-
pared to other bleeding-risk assessment scores during the first 
three months of anticoagulation (21). However, it is worth noting 
that robust validation of HAS-BLED in a large population is cur-
rently lacking. The present study provides some new evidence re-
garding the distribution of bleeding risk between DVT and PE pa-
tients as assessed with the HAS-BLED score, which may be in-
formative to a number of researchers in the field. Nonetheless, 
there are other risk factors for bleeding in VTE patients which are 
not accounted for by HAS-BLED, such as cancer, thrombocytope-
nia, diabetes, recent surgery, and frequent falls (17). These should 
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Figure 3: Treatment strategy overall (A and C) and within countries 
with DOAC launch at study commencement (B and D). DOAC, direct 
oral anticoagulant; DVT, deep-vein thrombosis; PE, pulmonary embolism; 
VKA, vitamin K antagonist. Multiple options possible for any one patient. 
DOAC launched countries are Germany, Austria, Switzerland, France and UK; 
Non-DOAC countries are Italy and Spain. *Delay in peak effect after initiation 
(2–5 days).
also be taken into account when determining risk. Several other 
scores have been suggested for use in the VTE setting, such as 
VTE-BLEED, which awards points for six clinical variables (active 
cancer [2 points]; male gender plus uncontrolled arterial hyperten-
sion [1 point]; anaemia [1.5 points]; history of bleeding [1.5 
points]; age ≥60 years [1.5 points]; and renal dysfunction [1.5 
points]) (22). This algorithm, which shares several similarities 
with the HAS-BLED score, was shown to be strongly predictive for 
major bleeding in 5,107 VTE patients on stable anticoagulation. 
Though guidelines currently advocate the presence of 1 (moderate 
risk) or ≥2 (high risk) out of 11 established risk factors as indi-
cators of a patient’s bleeding risk in VTE, further development and 
validation of existing algorithms such as HAS-BLED and VTE-
BLEED may replace such recommendations in future.
VTE treatment
Due to a combination of regulatory statuses, licencing, national 
and local guidelines and reimbursement at the time of the 
PREFER in VTE registry, DOAC use varied greatly between coun-
tries. Indeed, DOACs were only licensed and reimbursed in 
DACH, France and the UK. As a result, DOAC data was only fully 
analysed for these countries. Future analyses of this registry will 
evaluate the differences in treatment patterns between all included 
countries.
In the overall registry analysis, almost a quarter of patients were 
receiving a DOAC at baseline, with little variation between those 
in the DVT and PE groups (26.8 % vs 21.2 %). During this early 
phase of therapy, DOACs were more frequently used in younger 
patients, those without renal impairment, those at low risk of 
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Table 5: Overall out-
comes of VTE patients 
12 months after diag-
















All data are given as n/N (%). Multiple reasons could be given for a bleeding event. CRNM, clinically relevant non-major; DVT, 
deep vein thrombosis; PE, pulmonary embolism. *Proportional to all patients recorded at baseline. **Unless otherwise stated, 
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bleeding (according to HAS-BLED), and those with fewer comor-
bidities (such as diabetes). Concurrently, a similar registry which 
enrolled AF patients (PREFER in AF) also noted a low use of 
DOACs in higher-risk patients (23). This may be considered para-
doxical, given that the use of DOACs is thought to be more benefi-
cial in higher-risk patients, especially the elderly. A potential ex-
planation for this may be the reluctance of physicians to treat 
higher-risk patients with the newer agents at the time of the 
PREFER in VTE registry, likely due to a greater degree of famil-
iarity and confidence using VKAs. Other explanations may in-
clude a physicians being unwilling to switch patients from their 
historical agents, or a lack of understanding of the benefits of new 
agents. The latter may highlight a need for greater education in 
this area, especially given that results from pivotal phase III studies 
suggest that DOACs are as effective as VKAs with improved safety 
profiles (24–28). Indeed, a meta-analysis comparing the four ap-
proved DOACs with warfarin found that all of the DOACs had 
comparable efficacy with a significantly lower bleeding risk (29). 
These results and current guidelines suggest that there will be a 
paradigm shift towards higher DOAC use in the future; however, 
greater education efforts may be needed for many physicians to 
become comfortable with DOAC use. Data demonstrating the safe 
use of a predefined reduced DOAC dose for special subsets of pa-
tients (such as those with renal impairment or low bodyweight), 
may instil greater confidence in the medical professionals pre-
scribing them (24).
Outcomes
Overall outcomes at 12 months showed event rates that were con-
sistent with previous studies (2, 10, 24–28, 30, 31). VTE is a condi-
tion associated with significant mortality, and the rates seen were 
much higher than those found in clinical trial populations 
(24–28). The higher recurrence rates seen in DVT compared with 
PE patients may be related to treatment patterns, and this will be 
examined in future analyses. The rates of major, CRNM and nui-
sance bleeding and ischemic arterial events were as expected.
Limitations
While registries are generally more representative of a real-world 
population and not subject to the stringent inclusion/exclusion 
criteria restrictions of randomised control trials, a certain degree 
of sampling bias is unavoidable. Indeed, the majority of patients in 
the present study were diagnosed with VTE in the hospital setting, 
with approximately 40 % presenting with PE. “Although hospital 
diagnosis was not necessarily on an in-patient basis, these findings 
suggest that the registry may be more representative of those with 
more severe VTE, limiting generalisability. Furthermore, for coun-
tries where diagnosis and management predominantly occur out-
side of a hospital setting owing to differences in healthcare system 
structure, our findings may not necessarily be applicable. In addi-
tion, very elderly, frail patients are less likely to be able to give in-
formed consent and patients who died suddenly due to PE were 
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What is known about this topic?
• Venous thromboembolism (VTE) represents a significant health-
care burden and is the third most common cardiovascular disease 
in Europe.
• Much of the data available for the management of VTE are from 
clinical trials and may therefore not be representative of the full 
spectrum of VTE patients.
What does this paper add?
• Analysis of a large European cohort of VTE patients, finding that 
patients at moderate-to-high risk of bleeding are prevalent 
amongst those who have a VTE event.
• Almost a quarter of all presentations were for recurrent VTE, with 
>80 % of previous episodes having occurred more than 12 
months prior to baseline; hence VTE should be considered a 
chronic disease.
• Uptake of direct oral anticoagulants in Europe has been encour-
aging, with use particularly common in certain lower-risk sub-
groups.
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not included. Patients under 18 and those actively participating in 
a randomised, double blind interventional study were also ineli-
gible for enrolment, potentially excluding some younger, healthier 
subjects from the analysis. Finally, while one of the strengths of 
this registry is the large variety of sites, which reflects efforts to 
find a representative spread and account for national differences, 
confinement of study centres to Western Europe may limit extra-
polation of findings to other geographical areas.
Of further note is that patient histories, as with most studies, 
were based on a retrospective review of medical records. There-
fore, some incomplete or inaccurate data may be expected, reduc-
ing robustness. Furthermore, the degree of detail recorded may 
have been insufficient to reliably determine certain variables (such 
as type and severity of prior bleeding events), and the interpre-
tation of data by physicians may have introduced further subjec-
tive bias or inaccuracy. Thus, the reliability of data on events prior 
to baseline is not fully assured.
In terms of the data collected by telephone interview, a stan-
dardised patient diary was employed to record relevant events and 
limit recall bias. Notwithstanding this, the patient’s subjective 
evaluation of factors (such as bleeding severity) may have in-
fluenced the data collected. However, interviews were carried out 
by professionals with the appropriate medical knowledge and 
training to ensure standardised definitions were adhered to and 
further information could be sought from the patient’s medical 
practitioners. Therefore, data are assumed to be valid.
Future perspectives
Further analyses of the PREFER in VTE registry will provide new 
insights into the management of VTE patients in Western Europe. 
Evaluation of the follow-up data of these patients will provide evi-
dence for the changing clinical landscape in VTE treatment. Addi-
tionally, patient satisfaction and health-related quality of life will 
be analysed based on questionnaires completed at baseline and 
each follow-up.
Conclusions
The results confirm that VTE is a ubiquitous disorder occurring in 
many settings, and that in a real-world sample that is unrestricted 
by the confines of clinical trial inclusion/exclusion criteria, risk 
factors for bleeding are not uncommon. VTE is also a chronic dis-
ease, with initial events often taking place more than a year before 
subsequent episodes. DOAC use in Europe is fairly common, par-
ticularly amongst “lower-risk” patients at present; though this 
should extend into the higher-risk population as guideline recom-
mendations circulate and physician confidence in DOACs grows. 
Future analyses from the PREFER in VTE registry are therefore 
likely to identify changing treatment patterns reflecting recent 
changes to guideline recommendations.
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